Morphine-like compounds based on opium and derived from the opium poppy, Papaver somniferum, have been known for millennia, and their use recurs throughout the ages in personal reports and in world literature. For many decades their use was, if not fully condoned by society, tolerated as an effective means of ameliorating pain and indeed for ‘recreational’ purposes. The Opium Wars in the nineteenth century pitched the enthusiastic British traders in China against the local authorities who wished to control their use, with the eventual triumph of commercial capitalism and British firepower. In late nineteenth century London such opium
HughesJSmithTWKosterlitzHWFothergillLAMorganBAMorrisHR.Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature197518577–580. (https://doi.org/10.1038/258577a0)
GaillardRCGrossmanASmithRReesLHBesserGM. The effects of a met-enkephalin analogue on ACTH, β-LPH, β-endorphin and metenkephalin in patients with adrenocortical disease. Clinical Endocrinology198114471–478.
TsagarakisSNavaraPReesLHBesserGMGrossmanA. Morphine directly modulates the release of corticotrophin releasing factor-41 from rat hypothalamus in vitro. Endocrinology19891242330–2335. (https://doi.org/10.1210/endo-124-5-2330)
MorleyJEBaranetskyNGWingertTDCarlsonHEHershmanJMMelmedSLevinSRJamisonKRWeitzmanRChangRJVarnerAA.Endocrine effects of naloxone-induced opiate receptor blockade. Journal of Clinical Endocrinology and Metabolism198050251-257.
MoultPJGrossmanAEvansJReesLHBesserGM. The effect of naloxone on pulsatile gonadotrophin release in normal subjects. Clinical Endocrinology198114321–324. (https://doi.org/10.1111/j.1365-2265.1981.tb00202.x)
GrossmanAMoultPJACunnahDBesserGM. Different opioid mechanisms are involved in the modulation of gonadotrophin and ACTH release in man. Neuroendocrinology198642357–360. (https://doi.org/10.1159/000124463)
MendelsonJH EJJudsonBGoldsteinA.Plasma testosterone and luteinizing hormone levels during levo-alpha-acetylmethadol maintenance and withdrawal. Clinical Pharmacology and Therapeutics198435545–547. (https://doi.org/10.1038/clpt.1984.75)
LamprechtASorbelloJJangCTorpyDJInderWJ.Secondary adrenal insufficiency and pituitary dysfunction in oral/transdermal opioid users with non-cancer pain. European Journal of Endocrinology.2018178353–362. (https://doi.org/10.1530/EJE-18-0530)
SbardellaEIsidoriAMWoodsCArgeseNTomlinsonJWShineBJafar-MohammadiBGrossmanAB. Baseline morning cortisol level as a predictor of pituitary-adrenal reserve: a comparison across three assays. Clinical Endocrinology201786177–184. (https://doi.org/10.1111/cen.13232)
El-FarhanNPickettADucroqDBaileyCMitchemKMorganNArmstonAJonesLEvansCReesDA.Method-specific serum cortisol responses to the adrenocorticotrophin test: comparison of gas chromatography-mass spectrometry and five automated immunoassays. Clinical Endocrinology201378673–680. (https://doi.org/10.1111/cen.12039)